MM CAR-T to Upgrade Response BMTCTN1902
Summary
Third Opinion Trial Synopsis:
This experiment is called Phase II and it involves many doctors at different centers. They want to see if using special cells called "bb2121" can help people with multiple myeloma after they have a certain type of stem cell transplant.
This experiment is called Phase II and it involves many doctors at different centers. They want to see if using special cells called "bb2121" can help people with multiple myeloma after they have a certain type of stem cell transplant.
*Third Opinion AI Generated Synopsis
Trial Summary
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: